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Abstract
Introduction: The WHO recommends antiretroviral treatment (ART) for all HIV-positive patients regardless of CD4 count or
disease stage, referred to as “Early Access to ART for All” (EAAA). The health systems effects of EAAA implementation are
unknown. This trial was implemented in a government-managed public health system with the aim to examine the “real world”
impact of EAAA on care retention and viral suppression.
Methods: In this stepped-wedge randomized controlled trial, 14 public sector health facilities in Eswatini were paired and ran-
domly assigned to stepwise transition from standard of care (SoC) to EAAA. ART-na€ıve participants ≥18 years who were not
pregnant or breastfeeding were eligible for enrolment. We used Cox proportional hazard models with censoring at clinic tran-
sition to estimate the effects of EAAA on retention in care and retention and viral suppression combined.
Results: Between September 2014 and August 2017, 3405 participants were enrolled. In SoC and EAAA respectively, 12-
month HIV care retention rates were 80% (95% CI: 77 to 83) and 86% (95% CI: 83 to 88). The 12-month combined retention
and viral suppression endpoint rates were 44% (95% CI: 40 to 48) under SoC compared to 80% (95% CI: 77 to 83) under
EAAA. EAAA increased both retention (HR: 160, 95% CI: 115 to 221, p = 0.005) and retention and viral suppression com-
bined (HR: 4.88, 95% CI: 2.96 to 8.05, p < 0.001). We also identified significant gaps in current health systems ability to pro-
vide viral load (VL) monitoring with 80% participants in SoC and 66% in EAAA having a missing VL at last contact.
Conclusions: The observed improvement in retention in care and on the combined retention and viral suppression provides
an important co-benefit of EAAA to HIV-positive adults themselves, at least in the short term. Our results from this “real
world” health systems trial strongly support EAAA for Eswatini and countries with similar HIV epidemics and health systems.
VL monitoring needs to be scaled up for appropriate care management.
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1 | INTRODUCTION
In 2018, nearly 38 million people were living with human
immunodeficiency virus (HIV), of whom 20.64 million live in
sub-Saharan Africa. There has been a 56% decline in AIDS-re-
lated deaths from the peak of 1.7 million in 2004 to 770,000
in 2018, likely due to the three-fold increase in people receiv-
ing antiretroviral therapy (ART) since 2010 [1]. While there
has been significant progress to scale up HIV testing and
treatment, the incidence of HIV infection remains high, with
an estimated 1.7 million newly infected people in 2018 [1].
The HPTN 052 trial was first to demonstrate that early
antiretroviral (ART) initiation – referred to here as Early
Assess to ART for All (EAAA) – prevents viral transmission to
the uninfected partner in heterosexual HIV-discordant couples
[2]. To understand if the reported efficacy of EAAA would
have similar effectiveness in preventing transmission in sub-
Saharan Africa, four large community-based trials were
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launched between 2011 and 2013 [3-8]. These trials demon-
strated that there are significant implementation barriers to
EAAA for reducing HIV incidence in high-prevalence resource-
limited settings.
In 2014, the Eswatini Ministry of Health launched the Max-
ART stepped-wedge randomized controlled trial to implement
EAAA through the government-managed health system. Eswa-
tini has one of the highest HIV prevalence rates in the world,
27%, and an estimated annual incidence of 1.36% in adults
[9]. While the Eswatini Ministry of Health had made substan-
tial progress in addressing their HIV epidemic, there was
interest in identifying an effective, sustainable approach to
reduce the infection rate. Without this reduction, the number
of people needing HIV treatment in Eswatini will likely expand
along with the treatment costs.
In September 2015, the World Health Organization (WHO)
recommended ART irrespective of CD4 count (EAAA) [10]. As
high-prevalence countries adopt these new guidelines, the
MaxART trial offers evidence about the “real-world” impact on
retention and viral suppression under an EAAA approach. This
trial is registered at clinicaltrials.gov (NCT02909218).
2 | METHODS
This trial was designed and conducted by the MaxART Con-
sortium – led by the Eswatini Ministry of Health – from
September 2014 to August 2017. The trial methods and
power calculations have been reported elsewhere [11]. Briefly,
we implemented a clinic-based stepped-wedge design in which
the participating 14 clinics were randomly assigned in pairs,
matched by catchment size and geographic proximity, to shift
from standard of care (SoC) to EAAA at pre-specified dates.
After four months of baseline data collection in all clinics, one
pair of clinics transitioned at each four-month step. The last
pair was transitioned on 1 October 2016 instead of 1 January
2017, because on the former date, Eswatini changed its SoC
from CD4 ≤ 500 to EAAA. This change was approved by the
trial’s Data Safety Monitoring Board, Advisory Board, Primary
Research Team and the Eswatini Ministry of Health. The
health workers, trial participants and trial staff were blinded
to the timing of the clinic transition to minimize bias.
2.1 | Participants
ART-na€ıve, non-pregnant or breastfeeding HIV-positive partici-
pants, 18 years of age or older, with no mental illness were
eligible for the trial. Individuals who had already been initiated
on ART before the start of the trial were excluded. All eligible
participants were enrolled.
2.2 | Standard of care
Under SoC, participants meeting SoC ART eligibility criteria
were referred for ART initiation, while those who did not
were enrolled in pre-ART care. Pre-ART participants received
follow-up appointments to re-assess ART eligibility and screen
for tuberculosis symptoms in three-month intervals. Over the
course of the trial, changes to the national SoC for ART eligi-
bility were incorporated into the trial implementation. Prior to
1 December 2015, the national ART initiation threshold was
CD4 ≤ 350 and/or WHO Stage 3 or 4. On 1 December
2015, the threshold changed to CD4 ≤ 500 and/or WHO
Stage 3 or 4, and on 1 October 2016, Eswatini adopted EAAA
as SoC.
2.3 | Early access to ART for all
Under EAAA, all HIV-positive trial participants were eligible
for ART initiation irrespective of CD4 count or WHO stage.
Prior to the intervention, there were community sensitization
events with traditional leaders in the surrounding communi-
ties, and health talks and posters about EAAA at the partici-
pating clinics. Clinical mentors were also positioned at the
participating facilities to support the nursing staff with the
introduction of EAAA.
2.4 | Measurements
The primary endpoints – retention in HIV care and viral sup-
pression six months or more after ART initiation among those
retained – were chosen because they are proxy indicators for
long-term HIV-related health outcomes, mortality and trans-
mission [12,13]. We also present the effect of EAAA on a
combined endpoint of retention and viral suppression. The
results for several secondary endpoints (ART initiation, drug
resistance, HIV diseases progression, cost per patient per
year) for this trial are in preparation or under review at this
time. The results for patient satisfaction, adherence and mor-
tality have been published elsewhere [14-16].
The operational definitions of the primary endpoints, reten-
tion and viral suppression, were established according to the
definitions outlined by the Eswatini Ministry of Health Inte-
grated HIV Management Guidelines 2015 (Table 1). See Fig-
ures S1 and S2 for further details about these definitions. The
combined endpoint was defined as the date when either non-
retention in care or elevated viral load (VL) occurred, and sur-
vival time was the minimum of the times from enrolment to
any events qualifying for non-retention or elevated VL. Unlike
viral suppression, which considers the patients who survived
six months or more beyond ART-initiation, the combined end-
point is a fully randomized endpoint.
2.5 | Data collection and management
We measured the endpoints using routine data extracted from
the participants’ clinical records. We developed standard oper-
ating procedures for data management for transferring partici-
pant paper files to a trial-specific electronic database. Nurse
mentors regularly reviewed the participant files for accuracy
and completeness, and provided mentorship to the clinic staff.
The data manager and trial statistician generated monthly
error reports for data clerks and nurse mentors to resolve in
the clinics. In addition, the data manager conducted a quar-
terly quality assessment by reviewing 10% of paper records
with electronic data entry.
2.6 | Statistical analysis
We used Cox proportional hazard models for clustered data
to estimate the effect size, confidence intervals and p-values
whenever between-facility intra-class correlations (ICCs) were
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Table 2. Basic characteristics of MaxART participants at the time of trial enrolment
Standard of Care (n = 2034) EAAA (n = 1371) All ART na€ıve (n = 3405)
Demographic characteristics
Age at trial enrolment (year) median (q1, q3) 33 (28, 42) 33 (27, 40) 33 (27, 41)
Age group (years) n (%)
18 to <20 40 (2%) 34 (3%) 74 (2%)
20 to <30 679 (33%) 472 (34%) 1151 (34%)
30 to <40 722 (36%) 500 (36%) 1222 (36%)
40 to <50 354 (17%) 230 (17%) 584 (17%)
50 to <60 156 (8%) 97 (7%) 253 (7%)
60+ 83 (4%) 38 (3%) 121 (4%)
Sex n (%)
Male 695 (34%) 603 (44%) 1298 (38%)
Female 1339 (66%) 768 (56%) 2107 (62%)
Marital status n (%)
Married 1045 (52%) 634 (48%) 1679 (51%)
Divorced/widowed 127 (7%) 78 (6%) 205 (6%)
Single 825 (41%) 614 (46%) 1439 (43%)
Marital status missing, n (%) 37 (2%) 45 (3%) 82 (2%)
Education n (%)
Illiterate/primary 589 (40%) 384 (38%) 973 (39%)
Secondary 438 (30%) 362 (36%) 800 (32%)
High school 401 (27%) 218 (22%) 619 (25%)
Tertiary 48 (3%) 37 (4%) 85 (4%)
Education missing, n (%) 558 (27%) 370 (27%) 928 (27%)
Clinical characteristicsa
BMI (kg/m2) n (%)
<18.5 82 (4%) 81 (6%) 163 (5%)
18.5 to <25 971 (49%) 762 (57%) 1733 (52%)
25 to <30 529 (27%) 281 (21%) 810 (25%)
≥30 387 (20%) 212 (16%) 599 (18%)
BMI missing n (%) 65 (3%) 35 (3%) 100 (3%)
CD4 (cells/lL) n (%)
<350 804 (44%) 632 (56%) 1436 (49%)
350 to 500 441 (24%) 224 (20%) 665 (22%)
>500 591 (32%) 266 (24%) 857 (29%)
CD4 missing n (%) 198 (10%) 249 (18%) 447 (13%)
WHO stage n (%)
1 1074 (63%) 800 (63%) 1874 (63%)
2 357 (21%) 320 (25%) 677 (23%)
3 or 4 264 (16%) 146 (12%) 410 (14%)
WHO stage missing n (%) 339 (17%) 105 (8%) 444 (13%)
Screened for TB symptoms n (%)
Positive 190 (10%) 100 (8%) 290 (9%)
Missing screening for TB symptoms n (%) 82 (4%) 66 (5%) 148 (4%)
Viral load (copies/ml) n (%)
<1000 229 (12%) 120 (10%) 349 (11%)
1000 to <50‚000 781 (42%) 479 (40%) 1260 (41%)
50‚000 to <100‚000 213 (11%) 150 (13%) 363 (12%)
≥100‚000 661 (35%) 438 (37%) 1099 (36%)
Viral load missing n (%) 150 (7%) 184 (13%) 334 (10%)
Time between positive HIV test to trial enrolment (years) n (%)
≤1 1189 (59%) 1076 (79%) 2265 (67%)
1 to ≤3 421 (21%) 134 (10%) 555 (16%)
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greater than or equal to 0.01 [17,18]. Given the small number
of facilities, with very small ICCs, robust variances gave unre-
alistically small p-values [19]. Because there were a small num-
ber of facilities randomized, residual confounding is possible.
Thus, we conducted multivariable-adjusted analyses, where we
considered known and suspected baseline determinants of
retention and viral suppression, and included those with
p < 0.20 in the models [20]. Steptime was adjusted for in all
analyses, to ensure that any background time trends related
to quality of care or disease epidemiology did not lead to spu-
rious differences between the two groups. Survival curves
used the Breslow estimator and therefore needed to be esti-
mated at specific covariate values in the multivariate Cox
model from where the estimator was derived. The value of
each covariate, including steptime, was set at the mean value
of each person-visit in the study population (Table 2). Step-
wise restricted cubic splines were used to model continuous
covariates, to reduces bias due to incorrect assumptions about
linearity of the covariate-outcome relationships [21]. To fur-
ther adjust for any bias due to time trends not addressed by
the categorical steptime variable, when calendar time as a lin-
ear or non-linear effect was significant at p < 0.20 in any
model, it was included in the multivariate model in addition to
steptime. The missing indicator method was used to handle
missing covariate data [22]. In sensitivity analyses for the viral
suppression endpoint, Fine and Gray competing risk methods
were used, treating mortality not HIV- or ART-related as com-
peting risks [23]. Confidence intervals and p-values were not
adjusted for multiplicity [24]. Effect modification was assessed
by the robust score test, accounting for within-facility correla-
tion of the outcomes. Analysis of effect modification was con-
ducted among the subset of participants not missing each
covariate and adjusted for the baseline covariates given in
Footnote 1 of Tables S1,S2,S3.
The combined endpoint is a means of considering the
impact of the intervention on viral suppression with less need
for assumptions about those missing VLs. It has been reported
that 91.9% of those who report being on ART are virally sup-
pressed [25]. Thus, in sensitivity analysis, we varied the unsup-
pression rate among those missing VLs from 5% to 10% to
20%, randomly assigning those who experience the combined
endpoint through missing VL to being considered unsup-
pressed at the assumed percentage.
2.7 | Ethical approval
The trial was approved by the Eswatini National Health
Research Review Board on 17 July 2014 (MH/599C/FWA
000 15 267).
3 | RESULTS
The trial was conducted between September 2014 and
August 2017, during which 3485 participants were enrolled.
Following a priori exclusion criteria, 80 (2%) participants were
excluded, leaving 3405 eligible participants, of whom 2034
(60%) enrolled during the SoC phase of their clinic and 1371
(40%) under EAAA (Figure 1). From the distribution of enrol-
ment by clinic and step, we observed a larger sample size in
the earlier steps because existing pre-ART participants were
enrolled into the trial, whereas at later steps of the trial, only
participants who were newly diagnosed or who had previously
disengaged from pre-ART care remained available for enrol-
ment (Figure 2). Consequently, there were more participants
in SoC than EAAA.
Demographic characteristics did not vary appreciably
between the two study arms, with the exception of sex (34%
SoC and 44% EAAA of the enrolled participants were male).
Most clinical characteristics did vary between the study arms.
Notably, 79% of participants enrolled within a year of HIV
diagnosis in EAAA, compared to 49% in SoC, and 56%
Table 2. (Continued)
Standard of Care (n = 2034) EAAA (n = 1371) All ART na€ıve (n = 3405)
>3 413 (20%) 144 (11%) 557 (17%)
Time from trial enrolment to ART initiation
(months), median (q1, q3)
11 (5, 16) 0 (0, 0) 7 (0, 88)
Access to HIV Treatment supporter n (%)
Yes 1980 (97%) 1339 (98%) 3319 (97%)
Clinic characteristics
Level of clinic n (%)
Hospital 449 (22%) 349 (26%) 798 (23%)
Clinic with maternity ward 317 (16%) 181 (13%) 498 (15%)
Clinic without maternity ward 1268 (62%) 841 (61%) 2109 (62%)
Clinic volume by ART visits at baselineb n (%)
< Median (400 visits) 915 (45%) 385 (28%) 1300 (38%)
≥ Median (400 visits) 1119 (55%) 986 (72%) 2105 (62%)
a
Values within 90 days of enrolment and before ART initiation;
b
ART participant visits received during the first quarter into trial. Median number
of visits during this period is 400.
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enrolled with baseline CD4 ≤ 350 in EAAA compared to 44%
in SoC (Table 2).
Table 3 provides the steptime-adjusted incidence rates and
hazard ratios for the three endpoints. In SoC and EAAA,
respectively, the 12-month retention rates were 80% (95%
confidence interval (CI): 77 to 83) and 86% (95% CI: 83 to
88) (Figure 3). Under EAAA compared to SoC, a 60% signifi-
cant improvement in retention was observed (HR: 1.60, 95%
CI: 1.15 to 2.21, p = 0.005) (Table 3). Although VL coverage
was low in both the SoC and EAAA arms with 80% and 66%
of participants not receiving a VL between 180 days post-ART
initiation and end of follow-up, significant improvements of
increased viral suppression were also observed with EAAA
compared to SoC (HR: 14.51, 95% CI: 7.31 to 28.79,
p < 0.0001). In SoC and EAAA, respectively, the viral suppres-
sion rates, at 12 months post-ART initiation among those
retained, were 4% (95% CI: 2 to 7) and 79% (95% CI: 75 to
83) (Figure S3). Lastly, estimates for the combined endpoint
can be interpreted as an assessment of the impact of the
intervention on the third 90 of the HIV care cascade [26,27].
At one year, the cumulative incidence of retention and viral
suppression was 44% (95% CI: 40 to 48) under SoC com-
pared to 80% (95% CI: 77 to 83) under EAAA, and at two
years, it was 5% (95% CI: 3 to 9) under SoC compared to
60% (95% CI: 56 to 65) under EAAA (Figure S4). EAAA led to
a large significant increase in the combined endpoint (HR:
4.88, 95% CI: 2.96 to 8.05, p < 0.0001) (Table 3).
In addition, we carried out subgroup analyses in participants
eligible for ART at the time of enrolment under the current
SoC (“SoC eligible”), and in participants eligible only under
EAAA (“SoC ineligible”). There was strong evidence of similar
rates of improvement in retention, viral suppression at six
months or more after ART initiation, and the combined end-
point for both subpopulations (Table 3 and Figure S5). The
estimated effect sizes and significance levels for both reten-
tion and viral suppression increased after multivariable adjust-
ment (Table 3).
In our analysis, 74% of the unsuppressed VLs were due to
the lack of any measurements six months or more following
ART initiation. Among those lacking measurements, 50% of
those participants were missing VL due to no clinic visits dur-
ing this time, with the other 50% had missing VL despite hav-
ing had a least one clinical visit in this time window. In an
attempt to separate out the effects of EAAA itself from the
health system capacity to conduct adequate VL monitoring,
we conducted several sensitivity analyses, with multivariable-
adjusted results as follows: 1) Including only participants with
VL measured after baseline, the effect of EAAA on viral sup-
pression and ability to provide VL measurements six months
or more after ART initiation among those retained was 3.60
(95% CI: 2.13 to 6.09) times higher among those under EAAA
compared to SoC. 2) Considering the most extreme scenario
for those missing VLs – that participants enrolled under EAAA
were considered unsuppressed, and participants enrolled
under SoC were considered suppressed – we found that
EAAA participants were 2.09 (95% CI: 1.26 to 3.46) times as
likely to be suppressed by end of follow-up compared to SoC
participants. 3) Considering that those with missing VLs six
months or more following ART initiation were treated as sup-
pressed at all clinic visits, assuming that even if there were no
VLs recorded, participants were appropriately treated at their
visits, results were substantially attenuated in this analysis:
the steptime-adjusted HRs (95% CI, p-value) were 1.89 (1.13
to 3.17, 0.01) compared to 14.51 (7.31 to 28.79, <0.001) in
Figure 1. Flow diagram of participants enrolled during the control and intervention phases MaxART
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the original approach. These two results can be considered an
upper and lower bound on the effectiveness of EAAA on viral
suppression six months post ART initiation among those
retained. Since some participants attending clinic without VLs
were likely unsuppressed, if all VLs were available, the findings
would likely be somewhere in between these two bounds. Of
course, missed clinic visits leads to non-adherence, since the
provision of medications was matched to the clinic visit sched-
ule; thus, it is reasonable to treat missing clinic visits as
unsuppressed VLs. Clearly, the strong effect of EAAA on viral
suppression was both a function of the EAAA itself as well as
the enhanced health system capabilities. Competing risk analy-
sis for this endpoint produced HRs materially unchanged from
the primary analysis (data not shown).
Furthermore, in sensitivity analysis for the combined end-
point, as we varied the unsuppression rate among those with
missing VL from 5% to 20%, the benefit of the combined end-
point as HRs increased from 1.84 (95% CI: 1.23 to 2.77) to
2.20 (95% CI: 1.42 to 3.41), demonstrating that even with
very high suppression rates among those with missing VLs,
there was still an increased rate of retention and/or viral sup-
pression associated with EAAA.
Finally, after consideration of multiple comparisons, there
were only three significant instances of effect modification on
any of the three endpoints by covariates (Figures S6,S7,S8
and Tables S1,S2,S3). Viral suppression and the combined
endpoint varied significantly by facility level, with EAAA having
the strongest effect on these endpoints in hospitals, and the
weakest in clinics with no maternity facilities. We did not
assess effect modification by clinic for the viral suppression
endpoint because some clinics had no participants available
for assessment.
4 | DISCUSSION
This is the first randomized controlled trial to establish the
impact of EAAA on the critical endpoints of ART retention and
viral suppression in a “real-world” public sector health system
setting in sub-Saharan Africa. Increased retention and viral
suppression at six months or more after ART initiation was
observed with EAAA compared to SoC, similar to previous
observational data showing that those immediately eligible for
ART had higher retention rates under existing national guideli-
nes, than participants above the eligibility criteria [28,29].
EAAA led to both a 60% increase in retention rates and –
when considering documented viral load – a fivefold increase
in retention and viral suppression combined. VL suppression
can be considered a proxy measurement of health system effi-
ciency, simultaneously assessing retention, the ability of the
healthcare system to provide a VL result, and when available,
to maintain suppression. When only those with at least one VL
Figure 2. Number of enrolled participants by clinic pairs and steps. *Eswatini national guidelines for ART initiation changed from a CD4 count
threshold of ≤ 350 cells/lL to ≤ 500 cells/lL on December 1, 2016. **Eswatini’s national ART guidelines for ART initiation changed a CD4 count
threshold of ≤ 500 cells/lL or less to a universal test and treat approach on 1 October 2016
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Figure 3. Kaplan–Meier curves for retention. (a) all participants, (b) above SoC and (c) under SoC. Graphs reflect the cumulative incidence averaged over
covariates. Full multivariable model adjusted for steptime, age (18-<20 years old, 20-<30 years old, 30-<40 years old, 40-<50 years old,5 0-<60 year old,
60 + years old), sex, marital status (Married, Divorced/Widowed, Single), education (Illiterate/Primary, Secondary, High School, Tertiary), CD4 (<350, 350 to
500, >500), WHO stage (stage 1, stage 2, stage 3 or 4), BMI (<18.5, 18.5-<25, 25 to <30, ≥30), screened for TB symptoms (yes, no), viral load (<5‚000, 5
‚000 to 30‚000, >30‚000), access to HIV treatment supporter (yes, no), level of clinic (Hospital, Clinic with maternity, Clinic without maternity), time from
HIV tested positive to enrolment (≤1 year, 1- ≤3 years, >3 years), clinic volume (Low: < median, High: ≥ median). Missing data were treated as a separate
group for each of the covariates in the models. All adjusted variables were derived at study enrolment. Marginal model was used to adjust for clustering
effect among facilities. SoC-ineligible also included an additional variable for study enrolment date (continuous) in the model
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measurement post-ART are included, the 6- and 12-month
suppression rates were 0.94 and 0.91 in the EAAA partici-
pants, and 0.82 and 0.72 among SoC participants (Figure S3).
However, when we assume that those who died, were lost to
follow-up or were likely untreated due to not having VLs mea-
sured were all unsuppressed, as in the definition given in Fig-
ure S2, the six- and twelve-month suppression rates were
0.90 and 0.79 in the EAAA participants, and 0.22 and 0.04
among SoC participants. Most studies are likely estimating
suppression rates with these anti-conservative assumptions,
while the estimates we provided in our primary analysis may
be much closer to the reality and could explain, at least in
part, why transmission is still so high in, for example, Kwa Zulu
Natal, South Africa, bordering Eswatini [30]. Calendar time
was controlled for in all analyses, thus eliminating background
time trends related to a general improvement in the quality of
care as an explanation for the large observed increase in viral
suppression among the EAAA group.
Lessons learned from this trial are as follows: EAAA can be
successfully implemented in a public sector health system,
supporting Eswatini and other countries’ decisions to roll out
this policy as the SoC. EAAA adoption did not lead to a deteri-
oration of clinical performance of the public sector ART provi-
sion, as some had feared. Self-reported adherence and
disclosure levels remained high after the introduction of
EAAA, and we also observed an improvement in the health
care interactions, possibly due to training at participating facili-
ties, which will be an important element for a successful roll-
out of immediate ART [31]. Thus, EAAA not only benefited
those who are either newly diagnosed or enrolled in pre-ART
but also those who were eligible for ART prior to EAAA.
EAAA may be a particularly useful policy for providing ART
coverage to all people living with HIV while supporting the
attainment of the UNAIDS 90-90-90 target. Even in this
resource-limited, public sector clinical setting, EAAA partici-
pants were initiated on ART 3.6 fold faster than SoC partici-
pants (p < 0.001). As countries implement ART scale-up
programmes, there is also a need for policies and interven-
tions to sustain long-term retention and viral suppression
rates, such as increased access to viral monitoring for all par-
ticipants, mobile phone text messages for appointment remin-
ders and VL result delivery, and others [32-35].
This trial had several limitations. The Eswatini national ART
guidelines evolved during the trial from recommending ART
initiation at CD4 ≤ 350 to CD4 ≤ 500 and finally to EAAA.
These changes over time reduced the statistical power to
demonstrate significant impact of EAAA compared with the
SoC. However, because the effect sizes were of a greater
magnitude than anticipated, we were nevertheless able to
observe highly significant EAAA effects.
Another limitation of this trial resulted from a relatively
high proportion of missing VL measurements. In the primary
analysis, we treated all missing VLs as detectable. If VLs are
not measured as per national guidelines, it is difficult to prop-
erly treat participants, correct treatment failure and monitor
and address non-adherence. Insufficient VL monitoring is
equivalent to being unsuppressed from health systems, patient
safety and disease transmission standpoints. Under the
national guidelines, VLs are not measured until ART initiation
and every six months thereafter. Thus, even if SoC and EAAA
were compared contemporaneously, there would be more VLs
in the EAAA group since EAAA participants are immediately
initiated regardless of clinical status. However, the sensitivity
analyses demonstrated that regardless of whether we
included only those with at least one VL measurement after
baseline, considered all EAAA participants without VLs as
unsuppressed and SoC participants without VLs as sup-
pressed, or considered all participants with missing VLs sup-
pressed, results gave similarly attenuated but nevertheless
significant improvements in suppression rates.
These real-world limitations highlight the significant imple-
mentation challenges for the scale-up of VL testing. The rela-
tively poor performance in ensuring regular and timely VL
testing is in line with results from public sector ART pro-
grammes in six other sub-Saharan African countries [36].
Anecdotally reported reasons for the relatively poor VL test-
ing performance included unavailability of daily sample trans-
port, improper timing of sample pickups and a lack of
centrifuge and plasma storage capabilities. Our trial was con-
ducted under “real life” conditions. In contrast, at least two of
the trials testing the effect of EAAA on HIV incidence have
been carried out in a research-grade clinical trial setting sup-
ported by dedicated trial staff. In these trials, VL testing
occurred with adherence to recommended schedules that
exceeded the level achieved in public-sector provision in “real
life” [3,37]. The results from these studies could thus be con-
sidered closer to the efficacy end of the EAAA effect size
spectrum, while our results could be considered closer to the
effectiveness end of the spectrum.
5 | CONCLUSIONS
Our findings provide strong causal evidence for the benefits
of EAAA on retention and viral suppression, both for those
who were already eligible for ART under the previous eligibil-
ity thresholds and for those who became newly eligible under
EAAA. Thus, Eswatini and other countries with similar HIV epi-
demics and health systems should continue their rollout of
EAAA. EAAA policies will likely not only improve access to
ART but also the clinical performance of ART programmes
with respect to patient outcomes.
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